. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Cancer Causes Control. 2008 Oct 15;20(3):269–278. doi: 10.1007/s10552-008-9241-7

Table 1.

Characteristics of the validation study subgroup and the full NHS II Cohort (Mean ± SD)


	VALIDATION SUBGROUP	FULL NHS II COHORT
	n=296	n=85,092
Acrylamide intake (mcg/d)^*	19.3 ± 7.9	20.1 ± 8.4
AA intake by body weight (mcg/kg/d)	0.27 ± 0.12	0.29 ± 0.14
COVARIATES
Age (yrs)	47 ± 4	44 ± 5
BMI	27 ± 6	26 ± 6
% Past smokers	29%	26%
Parity	1.8 ± 1.2	1.9 ± 1.2
% Postmenopausal	48%	17%
Activity (MET-h/wk)	16 ± 18	18 ± 23
BLOOD LEVELS
Median AA-Hb (pmol/g) [range]	43.9 [14 –148]	-
Median GA-Hb (pmol/g) [range]	49.4 [23–157]	-
Median AA+GA Sum (pmol/g) [range]	94.3 [46–274]	-
Median GA:AA Ratio [range]	1.10 [0.6–2.6]	-

Acrylamide intake adjusted for total energy intake.